These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
3. The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation. Foss FM Semin Hematol; 2006 Apr; 43(2 Suppl 2):S35-43. PubMed ID: 16549113 [TBL] [Abstract][Full Text] [Related]
4. Nonmyeloablative stem cell transplantation: lessons from the first decade of clinical experience. Shimoni A; Nagler A Curr Hematol Rep; 2004 Jul; 3(4):242-8. PubMed ID: 15217553 [TBL] [Abstract][Full Text] [Related]
6. Nonmyeloablative stem cell transplantation for chronic myeloid leukemia. Qazilbash MH; Giralt SA; Champlin RE Hematol Oncol Clin North Am; 2004 Jun; 18(3):703-13, xi. PubMed ID: 15271401 [TBL] [Abstract][Full Text] [Related]
7. Clinical relevance of recipient leukocyte infusion as antitumor therapy following nonmyeloablative allogeneic hematopoietic cell transplantation. Saito TI; Rubio MT; Sykes M Exp Hematol; 2006 Sep; 34(9):1271-7. PubMed ID: 16939820 [TBL] [Abstract][Full Text] [Related]
8. Reduced-intensity conditioning for the treatment of malignant and life-threatening non-malignant disorders. Slavin S; Aker M; Shapira MY; Resnick I; Bitan M; Or R Clin Transpl; 2003; ():275-82. PubMed ID: 15387119 [TBL] [Abstract][Full Text] [Related]
9. Immunotherapy by allogeneic stem cell transplantation. Ringdén O Adv Cancer Res; 2007; 97():25-60. PubMed ID: 17419940 [TBL] [Abstract][Full Text] [Related]
10. Update on non-myeloablative stem cell transplantation for hematologic malignancies. Giralt S Int J Hematol; 2002 Aug; 76 Suppl 1():368-75. PubMed ID: 12430884 [TBL] [Abstract][Full Text] [Related]
17. Nonmyeloablative and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation: a clinical review. Pollack SM; O'Connor TP; Hashash J; Tabbara IA Am J Clin Oncol; 2009 Dec; 32(6):618-28. PubMed ID: 19593085 [TBL] [Abstract][Full Text] [Related]
18. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden. Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940 [TBL] [Abstract][Full Text] [Related]
19. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia. Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296 [TBL] [Abstract][Full Text] [Related]
20. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. Rizzieri DA; Koh LP; Long GD; Gasparetto C; Sullivan KM; Horwitz M; Chute J; Smith C; Gong JZ; Lagoo A; Niedzwiecki D; Dowell JM; Waters-Pick B; Liu C; Marshall D; Vredenburgh JJ; Gockerman J; Decastro C; Moore J; Chao NJ J Clin Oncol; 2007 Feb; 25(6):690-7. PubMed ID: 17228020 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]